What is cervical cancer? Cervical cancer is a malignant tumor that occurs in the region of the cervix. It has the second highest incidence of malignant tumors among women worldwide. However, among Chinese women, the incidence and mortality rate of cervical cancer are higher than breast cancer. The most susceptible site: the junction of squamous and columnar epithelium of the cervix C outside the cervical orifice. Under the stimulation of carcinogenic factors, cervical squamous epithelial cells gradually develop “atypical hyperplasia” (precancerous lesions), which will gradually develop into carcinoma in situ or even invasive carcinoma if not treated timely and thoroughly. There are about 465,000 new cases of cervical cancer in the world every year, and about 250,000 people die of cervical cancer every year. It accounts for 5% of all new cancer cases, and 80% of cases are in developing countries. In China, there are about 135,000 new cases each year, accounting for 30% of the total number of new cases of cervical cancer in the world, and about 53,000 people die from cervical cancer each year, usually after the age of 35, with the peak age between 45 and 50 years old, which is related to various factors such as chaotic sexual life, early pregnancy and multiple childbearing, and poor economic and health conditions. The task and challenge we face? Although 90% of cervical cancers can be effectively prevented by biennial screening, it is currently estimated that less than 5% of cervical cancers are prevented in China; currently, it is estimated that less than 1% of Chinese women aged 20-69 years receive routine liquid-based thin-layer cytology (referred to as TCT technology) every two years; women over 50 years of age almost never have smear tests, and their risk of invasive cervical cancer is Women over 50 years of age who almost never have smears are at high risk for invasive cervical cancer, especially in remote areas. Liquid-based thin-layer cytology (TCT) has become a keystone in the screening of cervical lesions and early cervical cancer. Liquid-based cytologic test, as the name implies, is a pathological examination and diagnosis of exfoliated cells preserved in a liquid matrix. The specific operation is roughly summarized as follows: preserving the exfoliated cells with a special preservation solution (liquid-based) (or improving the preservation effect of natural liquid-based by adding suitable reagents), so that the taken cell specimens are well fixed and preserved, and then, through different methods (automated instruments or pathology operation techniques), the cell specimens in the liquid-based matrix are made into thin and uniform smears, which are observed by the pathologist under the microscope and At present, thin layer cytology system (TCT) has become the nemesis of cervical and early cervical cancer screening. Cervical cancer is the second most common malignancy among women worldwide after breast cancer. It can occur in a wide age range, from 15 to 85 years. The highest incidence is around the age of 50. About 465,000 new cases of cervical cancer occur worldwide each year, and about 250,000 people die from cervical cancer each year. It accounts for 5% of all new cancer cases and 80% of cases are in developing countries. China has about 135,000 new cases each year, accounting for 30% of all new cases of cervical cancer in the world. In recent years, there is a trend of increasing the number of young cervical cancer cases year by year, especially at a rate of 2-3% per year. However, if early diagnosis and treatment are carried out, the efficacy is relatively good. In order to improve the diagnosis and treatment of cervical cancer, women of appropriate age must actively participate in cancer screening and have regular annual liquid-based thin-layer cytology examination.